BCRX · NASDAQ · STOCK
BioCryst Pharmaceuticals (BCRX) Stock Analysis
$8.56
52W $6.00 – $11.22
56/100
$2.17B
-5.9
0.55
Is BCRX Bullish or Bearish?
Bullish.
Innellis AI committee rates BioCryst Pharmaceuticals, Inc. (BCRX) Buy with a composite score of 56/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +18.61 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -1.39 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 68.7% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 2.09) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 68.7% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- News sentiment is positive (+0.33 across 3 articles, 14d) — News
Bear Case
- Price-to-book of 13.9x prices in significant intangible value — Value
- ROE of only -328.8% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.09 adds balance-sheet risk to the value case — Value
- High leverage (debt-to-equity 2.09) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
56/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 56%
of 192 Healthcare peers
Value Analyst
bearish
32
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 13.9x prices in significant intangible value
Growth Analyst
bullish
85
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 68.7% YoY -- genuine top-line momentum
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 2.09) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 3 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 56.4 to 56.4.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
57.2
Neutral
MACD Histogram
0.046
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Lh Ll
Support
$7.91
Resistance
$9.80
Bollinger %B
0.67
Inside Bands
Price vs Moving Averages
EMA 9
$8.33
Above
EMA 21
$8.51
Above
EMA 50
$8.88
Below
EMA 200
$8.83
Below
Fundamental Analysis
Valuation
100
Growth
60
Profitability
27
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
-5.9×
P/B Ratio
-4.79×
PEG Ratio
0.00
Dividend Yield
0.00%
52W High
$11.22
52W Low
$6.00
Quality & Growth
ROE
-22144.7%
ROA
5131.9%
Gross Margin
2351.6%
Operating Margin
-3329.3%
Revenue Growth YoY
—
Debt / Equity
-0.90
AI Fundamental Assessment
P/E ratio of -5.9 (inexpensive relative to a 15-40x range); Price-to-book of -4.8x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -221.4%; Return on assets of 51.3%; Net margin of -40.9%; Gross margin of 23.5%; Current ratio of 2.32 (healthy short-term liquidity); Debt-to-equity of -0.90; Free cash flow per share is positive (1.40); Most recent quarter beat estimates by 148.1%; EPS growth accelerating (-1000.0% -> +433.3% QoQ); Analyst estimates rising over recent quarters
Get the Full BCRX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →